31 results about "Bladder contraction" patented technology

Electrical stimulation of specific sensory nerves to control the filling and / or emptying of the urinary bladder. A wireless, injectable microstimulator is implanted into the soft tissues through which the sensory nerves pass, but where they are not normally accessible by conventional open surgical implantation of conventional electrical stimulators or electrodes with leads. In males, the dorsal penile nerves 6 are stimulated by a microstimulator injected into the dorsal quadrant of the penis. The activity induced in these nerves cause the spinal cord to generate reflex responses that result in relaxation of the detrusor muscle, increasing bladder capacity and preventing incontinence as a result of inappropriate bladder contractions. The sensory nerves, such as urethral afferents 4, supplying the urethra are stimulated by a microstimulator implanted into the corpus of the penis, adjacent to the urethra. The activity induced in the urethral afferents 4 cause the spinal cord to generate reflex responses that result in contractions of the detrusor muscle and relaxation of the sphincter 5, emptying the bladder.

It is an object of the present invention to provide a method and apparatus for enhanced bladder voidance which would have the advantages of a rhizotomy yet be temporary and reversible by combining low and high-frequency sacral nerve stimulation. Applicants propose a new sacral neurostimulation strategy based on a combination of nerve conduction blockade using high frequency signals and nerve stimulation using low-frequency signals. The method and apparatus enhances micturition in paraplegics by sacral neurostimulation involving a combination of a low-frequency electrical stimulation applied to one or more sacral nerves to induce bladder contraction and a high frequency electrical stimulation applied to at least one sacral nerve to cause nerve conduction blockade that prevents urethral sphincter dyssynergic contraction.

(R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or its salt shows a potent bladder relaxation effect in “isolated rat bladder smooth muscle relaxation test”, dose-dependently lowers the contraction frequency of rhythmic bladder contractions in “rat rhythmic bladder contraction measurement test” and, moreover, prolongs the urination intervals in “urination functions measurement test on cyclophosphamide-induced overactive bladder model rat”. Owing to these effects, the above compound is useful as a remedy for ovaractive bladder.

A method and system for bladder control are disclosed. In embodiments, a method for bladder control is provided that comprises coupling an electrode to an afferent nerve that is related to the bladder. Applying a plurality of pulse burst stimulations via the electrode causes voiding of urine from the bladder. In embodiments, the plurality of pulse burst stimulations to the afferent nerve reduces external urethral sphincter (EUS) contractions and evokes bladder contractions to expel urine from the subject. In embodiments, the plurality of pulse burst stimulations to the afferent nerve evokes bladder contractions alone to expel urine from the subject. In embodiments, a system for bladder control is provided that comprises an electrode for applying a pulse burst stimulus to an afferent nerve or dermatome to reduce reflex contractions and a signal generator for generating the pulse burst stimulus.

The invention discloses a method of regulating a stimulation frequency of a sacral nerve stimulator. The method comprises steps: two groups of stimulation electrodes are set; a stimulation changing period is set, wherein the stimulation changing period is a changing value; low-frequency impulses are transmitted to one stimulation electrode group and high-frequency impulses are transmitted to the other stimulation electrode group until the stimulation changing period is reached; in a next stimulation changing period, stimulation frequency signals of the two groups of stimulation electrodes are exchanged. The high-frequency and low-frequency combined electrical nerve stimulation is adopted to control contraction of bladder to empty the bladder, and generation of sphincter urethrae maladjusted contraction can also be avoided; the frequency amplitude in the low frequency part is changing, thereby avoiding fatigue on stimulation by nerve muscle; and only two stimulation points only need to be set, high-frequency and low-frequency stimulation is carried out alternatively at the two stimulation points, the problem of requiring multiple stimulation points is solved, and the operation difficulty is reduced.

A method and system for bladder control are disclosed. In embodiments, a method for bladder control is provided that comprises coupling an electrode to an afferent nerve that is related to the bladder. Applying a plurality of pulse burst stimulations via the electrode causes voiding of urine from the bladder. In embodiments, the plurality of pulse burst stimulations to the afferent nerve reduces external urethral sphincter (EUS) contractions and evokes bladder contractions to expel urine from the subject. In embodiments, the plurality of pulse burst stimulations to the afferent nerve evokes bladder contractions alone to expel urine from the subject. In embodiments, a system for bladder control is provided that comprises an electrode for applying a pulse burst stimulus to an afferent nerve or dermatome to reduce reflex contractions and a signal generator for generating the pulse burst stimulus.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and / or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and / or ameliorating underactive bladder.

A 6-oxo-7-oxa-B-Homo-cholesta-3-thionylhydrazone compound has the following chemical structural formula: the 6-oxo-7-oxa-B-Homo- Cholesta-3-thionylhydrazone compound is formed from cholesterol through the chemical method of PCC oxidation, NaBH4 reduction, Bayer-Villiger oxidation, Corrin oxidation and addition. Experiments have proved that the 6-oxo-7-oxa-B-Homo-cholesta-3-thionylhydrazone compound of the present invention has obvious inhibitory effect on various tumor cell lines, and can be used as in the application.

Since a compound represented by formula (I) wherein all of the symbols are the same as defined in the specification, a salt thereof, a solvate thereof, a prodrug thereof, a mixture with a diastereomer thereof in an arbitrary ratio, or a cyclodextrin clathrate thereof have a contracting activity of bladder detrusor and a relaxing activity of urethral sphincter, they can ameliorate bladder contraction dysfunction and / or urethral relaxation dysfunction, and for example, are effective for underactive bladder. Additionally, the compound of the present invention has little risk of side effects on the urinary system, the circulatory system and the digestive system, and exhibits excellent pharmacokinetics, such as oral absorbability etc. Therefore, the compound of the present invention is useful as a superior agent for preventing, treating and / or ameliorating underactive bladder.

The invention discloses a lotus balloon urinary catheter with a self-control urination function. The lotus balloon urinary catheter comprises a guide head, a lotus balloon, a fixing part, a tube body,a control tube, a guide wire, a duplex connecting tube, a self-control valve and a urine bag connecting tube; a connector is arranged at one end of the tube body, the lotus balloon is arranged at theother end of the tube body, the guide head is connected to the tail end of the lotus balloon which is formed by combining multiple strip-shaped bodies, the strip-shaped bodies are straightened and form a tubular body with the same inner diameter and the outer diameter as the tube body in an enclosing mode, the connector is connected with the control tube, one duplex connecting tube is connected to the other end of the control tube, the self-control valve is connected to the other end of the duplex connecting tube, the urine bag connecting tube is connected to the other end of the self-controlvalve, the guide wire penetrates through the tube body, one end of the guide wire is connected with the control tube, and the other end of the guide wire is connected with the guide head. Accordingly, by means of the self-control valve, urination can be manually controlled, and the bladder contraction function is recovered conveniently. Different fixing parts can be selected according to the gender, fixation of the urinary catheter is firm, and urine leaking from the gap between the urinary catheter and the urethra can be collected.

The invention discloses an intubation-free negative pressure suction urethral catheterization device in the intubation-free urethral catheterization technology. The device is composed of a vacuum pump, a urine storage bottle and a covering cup, which are connected through ducts. The vacuum pump promotes urethral peripheral tissues to generate centrifugal expansion through suction force generated by the covering cup when forming negative pressure, and the covering cup generates urethral passive traction to expand the urethral lacuna to facilitate outflow of urine. An additional vibration massager massages the bladder part and related acupuncture points to induce bladder contraction so as to recover the urinary function. When not in use, no catheter is needed to be inserted to avoid infection, pain and such complications as mucosa damage, etc.

The present invention relates to methods for reducing the frequency of bladder contractions without significantly affecting micturition pressure, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt or prodrug thereof. The method can be used to treat bladder dysfunction without significantly increasing residual volume, including urgency, frequency, pollakiuria, nocturia, low deferment time, suboptimal volume threshold, neurogenic bladder, or combinations thereof.

The embodiment of the invention discloses a bladder function rehabilitation training system and method. The bladder function rehabilitation training system comprises a sacculus, a drainage tube, a control valve, a control unit and a drainage bag; the sacculus is communicated with one end of the drainage tube, the drainage bag is communicated with the other end of the drainage tube, the two ends ofthe control valve are communicated with the drainage tube, and opening and closing of the drainage tube are controlled through a control unit; the control unit comprises a controller, a power supplyunit, a time relay, a pressure sensor and a flow instrument, a pressure cavity is formed between a sliding block and a front end tube, a liquid flow cavity is formed between the sliding block and a tail end tube, the controller is in communication connection with the pressure sensor in the pressure cavity and the flow instrument and the power supply unit which are arranged in the liquid flow cavity, the power supply unit is electrically connected to an electric push rod, and the electric push rod is controlled to stretch out and draw back. According to the bladder function rehabilitation training system, flow of urine of a patient can be sufficient, the bladder contraction and filling can be sufficient, and the bladder exercise can be achieved.

The invention discloses a bladder electromyographic signal detecting device, which adopts a wearable magnetic field generating device to generate an alternating magnetic field in a bladder portion ofa patient, and uses a diaphragm on a detecting head to transmit an acoustic wave signal generated by the magnetoacoustic coupling effect in the bladder cavity, the acoustic wave signal is detected bya high-sensitivity microphone and converted into an electrical signal, and the electrical signal is processed by a processing module to obtain information of the bladder electromyographic signal, thebladder electromyographic signal can be effectively detected, non-invasive measurement is realized, the pain caused to patients is realized, and the cost of testing equipment is low. The invention also discloses a detection system, which uses the bladder pressure detecting device to detect the bladder pressure, and combines the bladder myoelectric signal, which can facilitate the doctor to intuitively analyze the relationship between the bladder contraction activity and the detrusor myoelectric activity. The detection system also includes an urination device that facilitates patient urinationduring the detection process.

The invention relates to a novel gall bladder contraction poison receptor antagonist analogue with a structure as shown in the specification. A synthetic method of the novel gall bladder contraction poison receptor antagonist analogue includes enabling L-methionine, serving as a raw material, to react with 5-methylisatoic anhydride to obtain seven-membered ring lactam, performing selective acylation on the seven-membered ring lactam and substitutional benzoyl chloride, and performing nitro-reduction and dehydration to form quinazolinone rings to further obtain the novel gall bladder contraction poison receptor antagonist analogue. The obtained target compound is brand new, synthetic route is short, operation and separation in each step are simple, yield is high, reagents are common and cheap, and accordingly, the compound is suitable for mass production.

The invention provides a noninvasive bladder biofeedback training instrument. The noninvasive bladder biofeedback training instrument is provided with a bladder capacity measuring device, a player and an audio playing controller, wherein the bladder capacity measuring device is used for collecting a bladder capacity value; the player is used for storing and playing light music audio materials and meditation type respiration guiding voice materials; the audio playing controller is provided with a bladder capacity analysis module, a bladder contraction state analysis module, an audio material switching module and a timer; the bladder capacity analysis module and the bladder contraction state analysis module are respectively used for analyzing the change conditions of the bladder capacity value and a bladder contraction state; and when a rule is met, an instruction is sent to the audio material switching module to further control the playing content of the player, and meanwhile, an instruction is sent to the timer to control the closing of the player. The invention also provides a non-treatment-destination method for determining bladder contraction stability. According to the invention, training effect on urination dysfunction can be improved, and research on a relation between the urination dysfunction and the bladder function is promoted.

The present inventors achieved the present invention on the basis of the knowledge that a thiazole derivative with a pyrazine-2-carbonylamine substituent at the second carbon position is an excellent positive allosteric modulator of the muscarinic M3 receptor and is useful as a prophylactic and / or therapeutic agent against bladder / urinary tract disorders associated with bladder contractions induced by the muscarinic M3 receptor. A 2-acylaminothiazole derivative or a salt thereof according to the present invention can be used as a prophylactic and / or therapeutic agent against bladder / urinary tract disorders associated with bladder contractions induced by the muscarinic M3 receptor, including, for example, urinary disorders such as underactive bladder. (In the formula, R1 is -(N(-R11)(-R12) or an optionally substituted cyclic amine; R11 is a C1–6 alkyl; R12 is an optionally substituted C1–6 alkyl or an optionally substituted C3–8 cycloalkyl; R2 is an optionally substituted aryl, an optionally substituted monocyclic aromatic heterocycle, or an optionally substituted bicyclic aromatic heterocycle; and R3 is -H,-OH, -O-( C1–6 alkyl), or a halogen.)

The invention discloses an adjusting method of stimulation frequency of a sacral nerve stimulator. The adjusting method comprises steps of setting two groups of stimulation electrodes; setting a stimulation change period, which is a fixed value; sending low frequency pulses to one group of the stimulation electrodes, and sending high frequency pulses to another group of the stimulation electrodes until the stimulation change period is reached; and in the next stimulation change period, exchanging stimulation frequency signals of the two groups of stimulation electrodes. According to the invention, by combining low frequency and high frequency, and electrical nerve stimulation, a bladder is controlled to contract and be fully discharged, and imbalanced contraction of the urethral sphincter is avoided; parts of frequency amplitude values in low frequency are changed, so fatigue to stimulation of nerves and muscles is avoided; only two stimulation points are set and high frequency stimulation and low frequency stimulation are alternatively performed at the two stimulation points, so a problem of the requirement of multiple stimulation points is avoided and difficulty level of an operation is reduced.

Provided are compounds useful as active ingredients of pharmaceutical compositions for treating urinary storage disorders, voiding disorders, and lower urinary tract diseases. The inventors have found that thiazole derivatives substituted at the 2-position of pyrazine carbonylamino are excellent muscarine M 3 receptor positive allosteric modulator, and it is expected to act as the same as muscarinic M 3 A prophylactic or therapeutic agent for bladder / urological diseases related to receptor-mediated bladder contraction, thereby completing the present invention. Expect 2-acylaminothiazole derivatives or salts thereof of the present invention as 3 A prophylactic or therapeutic agent for bladder / urological diseases related to receptor-mediated bladder contraction (such as voiding disorders such as hypoactive bladder).

The invention provides a bladder function auxiliary training device, which includes a pressure detection device, a signal amplification module, a main control unit, and a switch assembly; the pressure detection device is electrically connected to the signal amplification module, the signal amplification module is connected to the main control unit, and the main control unit Electrically connected with the switch assembly. The invention realizes the maintenance and training of the patient's bladder pressure by collecting bladder pressure information, matching the patient's bladder pressure information and the volume of bladder fluid. The invention greatly reduces the workload of medical personnel, and can maintain the good function of bladder contraction and expansion of the patient, so as to ensure the good recovery of the patient after being discharged from the hospital. The invention promotes a leap in critical disease monitoring technology and has great industrialization prospects.

The invention discloses a power-assisted urination device and a control method. The power-assisted urination device comprises a urination tube, a plunger pump and a head controller, wherein a positioning air bag is arranged outside the urination tube; the plunger pump comprises a pump body and a plunger, and a magnet exciting coil is arranged outside the pump body; and the head controller comprises a sensor, a processor, a power supply and a shell. The plunger pump is connected with the urination tube, and the urination tube is fixed in the urethra through the positioning air bag. The head controller is used for controlling opening and closing of the plunger pump, and when urination is needed, the head controller controls the plunger pump to be started, so that urine is driven by the plunger pump to flow through the urination tube and then flow out, and the problem of patients with bladder contraction weakness indications can be solved. In addition, due to the fact that the urine has acertain speed when being discharged, the urine can flush the urethra, and the urethra is kept sanitary. The urination tube does not need to extend out of the body, so that the movement convenience ofa user is improved, and the discomfort is reduced; and the urethra can be naturally contracted after urination, so that the contraction function is maintained, and the infection risk is also reduced.

To provide a compound useful as an active ingredient of a pharmacological composition for the treatment of urinary storage symptoms, dysuria, lower urinary tract diseases, and the like. The inventors perfected the present invention after discovering that thiazole derivatives substituted at position 2 by pyrazinylcarbonylamino are exceptional muscarinic M3 receptor positive allosteric modulators and can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors. The 2-acylaminothiazole derivatives or salts thereof of the present invention can be expected to serve as agents for the prevention or treatment of urinary bladder and urinary tract diseases involving bladder contraction mediated by muscarinic M3 receptors, e.g., underactive bladder and the like.